Compounds and methods for inhibiting .beta.-protein filament formation and neurotoxicity
AssigneePresident and Fellows of Harvard College
InventorHuntington Potter
Life of this patent
Estimating the term…
Abstract
Methods of treating an individual with Alzheimer's Disease by administering to the patient a therapeutically effective dose of a compound which interferes with the interaction between Alzheimer .beta.-protein and Apolipoprotein E4 or .alpha..sub.1 -antichymotrypsin, thereby suppressing the formation of Alzheimer .beta.-protein filaments and the neurotoxic effects of these filaments. The present invention also refers to methods of screening for compounds which are effective drugs for treating Alzheimer's disease. These methods comprise screening for compounds which suppress the formation of Alzheimer .beta.-protein filaments in the presence of promoting factors and which suppress the neurotoxic effects of these filaments formed in the presence of promoting factors.
Claims6
An oligopeptide, wherein the oligopeptide is selected from the group consisting of A.beta..sub.2-9, a fragment of A.beta..sub.2-9 or a modified fragment of A.beta..sub.2-9, wherein the oligopeptide binds .alpha..sub.1 -antichymotrypsin.
An oligopeptide, wherein the oligopeptide is A.beta..sub.2-9 or a fragment thereof, wherein the oligopeptide binds .alpha..sub.1 -antichymotrypsin.
An oligopeptide, wherein the oligopeptide is a fragment of A.beta..sub.1-12, or a modified-fragment of A.beta..sub.1-12, wherein the oligopeptide binds .alpha..sub.1 -antichymotrypsin, with the proviso that the oligopeptide is not A.beta..sub.1-10.
An oligopeptide, wherein the oligopeptide is a fragment of A.beta..sub.12-28 or a modified fragment of A.beta..sub.12-28, wherein the oligopeptide binds ApoE4, with the proviso that the oligopeptide is not A.beta..sub.17-20 or A.beta..sub.18-28.
Dependencies are inferred from the claim text.